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A computational analysis identified TET proteins as mammalian homologs of the 
trypanosome J-binding proteins, JBP1 and JBP2 that have been proposed to 
oxidize the 5-methyl group of thymine.  We tested the hypothesis that TET proteins 
modify 5-methylcytosine in DNA.  Here we show that TET1, previously 
characterized as a fusion partner of the MLL gene in acute myeloid leukemia, is a 2-
oxoglutarate (2OG)- and Fe(II)-dependent oxygenase that catalyzes the conversion 
of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (hmC) in cultured cells and 
in vitro.  Expression of TET1 in HEK293 cells led to a decrease in 5mC as judged by 
immunocytochemistry, with concomitant appearance of a novel nucleotide 
identified by mass spectrometry as hmC.  The catalytic domain of TET1 converted 
5mC to hmC in vitro, whereas a variant with substitutions in residues predicted to 
bind the catalytic Fe(II) did not generate hmC.  hmC can be detected in the genome 
of mouse ES cells and both TET1 levels and hmC levels decline when ES cells are 
differentiated.  RNA-interference-mediated depletion of TET1 results in a decrease 
in hmC levels in ES cells.  Our results suggest that hmC is a normal constituent of 
mammalian DNA, and identify TET1 as an enzyme with a potential role in epigenetic 
regulation through modification of 5mC.     3 
Introduction 
5-methylcytosine (5mC) is a minor base in mammalian DNA. It constitutes ~1% of all DNA 
bases and is found almost exclusively as symmetrical methylation of the dinucleotide CpG 
(1).  The majority of methylated CpG is found in repetitive DNA elements, suggesting that 
cytosine methylation evolved as a defense against transposons and other parasitic 
elements in DNA (2, 3).  Indeed, loss of the DNA methyltransferase Dnmt1 in mice results 
in reactivation of a class of retrotransposons in somatic cells (4).  Methylated CpGs are 
mutagenic; the modified cytosine is prone to deamination to yield thymine, thus generating 
T:G mismatches which if unrepaired result in C to T transitions.  This mechanism has 
been proposed to effect a slow but progressive inactivation of retrotransposons in the 
genome (2). 
Methylation patterns in mammals are remarkably dynamic during early embryogenesis, 
when CpG methylation is essential for establishing X-inactivation and the asymmetric 
expression of imprinted genes (5, 6).  In somatic cells, CpG islands in genes that are not 
expressed are often highly methylated.  DNA methylation enables the recruitment of 
methyl-CpG binding proteins such as MeCP2 and Kaiso; these in turn recruit histone 
deacetylases and other chromatin-modifying complexes that create a repressed chromatin 
environment, ultimately resulting in chromatin compaction and gene silencing (7, 8).  In 
addition, CpG methylation may directly interfere with the binding of certain transcriptional 
regulators to their cognate DNA sequences (9), as best shown for the insulator-binding 
protein CTCF which controls the reciprocal expression of the imprinted genes Igf2 and 
H19 on paternal and maternal chromosomes respectively (10).  DNA methylation patterns 
are highly dysregulated in cancer, and changes in methylation status have been 
postulated to inactivate tumor suppressors and activate oncogenes, thus contributing to 
tumorigenesis (11).   
The enzymes that methylate DNA in mammals have been thoroughly characterized.  Two 
de novo methyltransferases, DNMT3A and DNMT3B, symmetrically methylate 
unmethylated DNA (12), whereas the maintenance methyltransferase, DNMT1, maintains 
the established patterns of DNA methylation by methylating CpGs during DNA replication 
(3, 10).  Preventing maintenance methylation through successive replication cycles 
progressively dilutes the methyl mark and results in “passive” DNA demethylation, a 
process well-documented to occur in differentiating cells (13).  An “active” enzymatic 
mechanism of DNA demethylation has also been postulated; the most convincing   4 
example involves the genome-wide demethylation of the paternal genome that occurs 
shortly after fertilization, independently of DNA replication (14-16).  Potential mechanisms 
for active demethylation include (i) a thermodynamically unfavorable cleavage of the 
carbon-carbon bond linking the methyl group to the pyrimidine, resulting in release of the 
methyl moiety; and (ii) a repair-like process in which the methylated base or nucleotide is 
excised and the lesion is then repaired to replace the original 5mC with an unmethylated 
C (reviewed in (5, 17)).  This latter mechanism occurs in plants, where DEMETER, a 
bifunctional glycosylase restricted to flowering plants, cleaves the glycosidic bond of 5mC 
and stimulates insertion of an unmethylated C through base-excision repair (18).  A 
variety of candidate mammalian demethylase activities have been described, but 
unfortunately, none of these reports have been confirmed by other laboratories (reviewed 
in (19-21)).   
In trypanosomes, a potential analog of 5-methylcytosine is a modified version of thymine 
called base J (β-D-glucosyl hydroxymethyluracil), which appears to be derived by 
hydroxylation of thymine followed by glucosylation (22).  Base J is thought to play an 
important role in silencing gene transcription.  It is present in silenced copies of the genes 
encoding the variable surface glycoprotein (VSG) responsible for antigenic variation in the 
host, but is absent from the single expressed copy (23, 24).  A J-binding protein, JBP1, 
and a homolog, JBP2, were identified biochemically and through homology searches 
respectively (22, 24).  JBP1 and JBP2 are enzymes of the 2OG and Fe(II)-dependent 
oxygenase superfamily (22), and mutations of the predicted Fe(II)- and 2OG-coordinating 
residues in JBP1 and JBP2 lead to decreased levels of base J in trypanosome and 
Leishmania DNA.  Based on these data, the authors proposed that JBP1 and JBP2 
oxidize the 5-methyl group of thymine in the first step of J biosynthesis (22, 25, 26) 
We speculated that homologs of JBP1 and JBP2 might be generally involved in 
modification of 5-methylpyrimidines, including thymine and 5-methylcytosine.  
Computational analysis identified the TET family of proteins (TET1, TET2 and TET3) as 
likely homologs with predicted 2OG and Fe(II)-dependent oxygenase activity.  Here we 
show that TET1 catalyzes the conversion of 5mC to hmC both in cells and in vitro.  
Moreover, we demonstrate that hmC is present in the genome of undifferentiated ES cells, 
but is not detectable in genomic DNA of two differentiated cell types, previously-activated 
human T cells and mouse dendritic cells.  TET1 and hmC levels diminish in parallel when 
ES cell differentiation is induced by withdrawal of the cytokine LIF, and RNAi-mediated   5 
depletion of TET1 in ES cells results in decreased hmC.  These studies define a new 
class of enzymes that catalyze a new modification of DNA, and modify our perception of 
how DNA methylation status may be regulated in mammalian cells.   
 
RESULTS  
Identification of a novel family of 2OG-Fe(II) oxygenases with predicted 5-
methylpyrimidine oxidase activity 
To identify candidate enzymes that catalyze the oxidative modification of 5-
methylcytosine, we created a position-specific score matrix (profile) of known 2OG-Fe(II) 
oxygenases that included the predicted oxygenase domains of JBP1 and JBP2 (Suppl. 
Fig. S1).  We used this profile to conduct a systematic search of the non-redundant 
database using the PSI-BLAST program (27).  This search recovered homologous 
domains in the gp2 proteins from the mycobacteriophages Cooper and Nigel and a related 
prophage from the Frankia alni genome (e<10
-4).  We then generated a new profile which 
included the gp2 protein sequences, and performed a second search of the protein 
sequence database of microbes from environmental samples.  This search detected 
numerous homologous proteins potentially derived from uncultured marine phages and 
prophages.  A further search of the non-redundant database, with the newly-detected 
proteins from the environmental sequences added to the profile, recovered homologous 
regions in the three paralogous human oncogenes TET1 (CXXC6), TET2 and TET3 and 
their orthologs found throughout metazoa (e<10
-5).  Homologous domains were also found 
in fungi and algae.  In PSI-BLAST searches, these groups of homologous domains 
consistently recovered each other prior to recovering any other member of the 2OG-Fe(II) 
oxygenase superfamily, suggesting that they constitute a distinct family (LM Iyer, L 
Aravind, manuscript in preparation).  
To confirm the relationship of the newly-identified proteins (hereafter referred to as the 
TET/JBP family; see legend to Fig. 1) with classical 2OG-Fe(II) oxygenases, we prepared 
a multiple alignment of their shared conserved domains and used this to generate a 
hidden markov model (HMM).  A profile-profile comparison of this HMM against a library 
of HMM’s generated for all structurally-characterized domains from the Protein Database 
(PDB) with the HHpred program (28) resulted in recovery of prolyl hydroxylase (e<10
-12), a 
canonical member of the 2OG-Fe(II) oxygenase superfamily, as the best hit.  Secondary   6 
structure predictions suggested the existence of an N-terminal α-helix followed by a 
continuous series of β-strands, typical of the double-stranded β-helix (DSBH) fold of the 
2OG-Fe(II) oxygenases (29) (Fig. 1A, bottom).  A multiple sequence alignment (Fig. 1A) 
further showed that the new TET/JBP family displayed all of the typical features of 2OG-
Fe(II) oxygenases including: (i) the HxD signature, just downstream of an N terminal β-
strand which chelates Fe(II) (x is any amino acid); (ii) a small residue, usually glycine, at 
the beginning of the strand immediately downstream of the HxD motif, which helps in 
positioning the active site arginine; (iii) the Hxs motif (where s is a small residue) in the C-
terminal part, in which the H chelates the Fe(II) and the small residue helps in binding the 
2-oxo acid; (iv) the Rx5a signature (where a is an aromatic residue) downstream of the 
above motif – the R in this motif forms a salt bridge with the 2-oxo acid and the aromatic 
residue helps position the first metal-chelating histidine (the key residues are marked with 
asterisks in Fig 1A).  These observations strongly suggested that members of the 
TET/JBP family, including TET1, 2 and 3, are catalytically-active 2OG-Fe(II) oxygenases.   
Additionally, the metazoan TET proteins contain a unique conserved cysteine-rich region, 
contiguous with the N-terminus of the DSBH region, which possesses at least eight 
conserved cysteines and one histidine that are likely to comprise a binuclear metal cluster 
(Fig. 1A, top). Vertebrate TET1 and TET3, and their orthologs from all otheranimals, also 
possess a CXXC domain, a binuclear Zn-chelating domain with eight conserved cysteines 
and one histidine, located N-terminal to the 2OG-Fe(II) oxygenase domain (shown 
schematically for TET1 in Fig. 1B).  Analysis of the architectures of CXXC domain proteins 
suggests that  the CXXC domain is an accessory DNA-binding domain, that tends to be 
combined in the same polypeptide with a variety of domains that possess diverse 
chromatin-modifying and modification recognition activities.  The CXXC domain is found in 
several chromatin-associated proteins, including the methyl-DNA-binding protein MBD1, 
the histone methyltransferase MLL, the DNA methyltransferase DNMT1 (30) and the 
lysine demethylases KDM2A (JHDM1A/ FBXL11) and KDM2B (JHDM1B/FBLX10, which 
also contains a ubiquitin E3 ligase domain) (31), and in certain cases has been shown to 
discriminate between methylated and unmethylated DNA (32).  
Taken together, the contextual information gleaned from these domain architectures and  
from gene neighborhoods in the bacteriophage members (Supplementary Information and 
LM Iyer, L Aravind, manuscript in preparation) supported a conserved DNA modification 
function for the entire TET/ JBP family, namely oxidation of 5-methyl-pyrimidines.  In this   7 
study we tested the specific hypothesis that TET proteins might operate on 5mC to 
catalyze oxidation or oxidative removal of the methyl group, focusing on TET1 as a 
mammalian example of the TET/JBP family.   
 
Cells overexpressing TET1 show decreased staining for 5-methylcytosine 
To determine whether increasing the amount of TET1 expression would alter the global 
levels of 5mC in cells, we expressed HA-tagged full-length TET1 in HEK293 cells.  Two 
days after transfection, cells were fixed, doubly stained with antibodies specific for 5mC 
and for the HA epitope, and processed for immunocytochemistry (Fig. 2A).  To quantify 
the relation between HA (TET1) and 5mC staining at a single-cell level in each cell in a 
given field, the intensities of HA and 5mC staining were measured in each pixel within an 
area defined as the cell nucleus by DAPI staining (CellProfiler
TM image analysis software, 
Suppl. Fig. S2).  The mean pixel intensity for each cell analyzed is represented by a dot in 
Fig. 2B.  
Mock-transfected cells showed substantial variation in 5mC staining intensity (Fig. 2A, top 
panel), either because 5mC levels vary from cell to cell or because the accessibility of 
5mC to the antibody differs among cells due to technical considerations (e.g. incomplete 
denaturation of DNA).  This spread in staining intensity is obvious in Fig. 2B, in which 
mock-transfected cells are represented by blue dots and enclosed in a dotted oval.  In 
cells transfected with TET1, there was a strong visual correlation of HA positivity with 
decreased staining for 5mC (Fig. 2A, middle panel).  The population of HA-low cells, 
presumed to be untransfected, showed a spread of 5mC staining intensity similar to that 
of the mock-transfected population (Fig. 2B, left panel, note overlapping red and blue dots 
at low HA intensities), whereas the productively transfected (HA-high) cells showed a 
clear decrease in 5mC staining intensity (Fig. 2B, left panel, note uniformly low 5mC 
staining intensity in the red HA-high dots).   
In addition to wild-type TET1, we tested the effect of a mutant TET1 bearing H1671Y, 
D1673A substitutions predicted to impair Fe(II) binding.  Cells expressing this mutant 
protein did not show decreased staining for 5mC; rather, both visual and quantitative 
analysis indicated that cells expressing high levels of HA could also display high levels of 
5mC staining (Fig. 2A, bottom panel; Fig. 2B, right panel; see quantification in Fig. 2C).    8 
These results are consistent with the hypothesis that the H1671Y, D1673A mutations 
compromise a biological function of TET1. 
 
An unidentified nucleotide derived from 5mC is present in HEK293 cells expressing 
TET1 
To determine more quantitatively whether TET1 overexpression affects the intracellular 
levels of 5mC, we used an approach that allowed us to measure the ratio of 5mC to C at a 
subset of genomic CpG sites (those present in sequences recognized by the methylation-
insensitive restriction enzyme MspI) (33).  For these experiments we used full-length 
TET1 (TET1-FL) as well as the predicted catalytic domain of TET1 (TET1-CD, comprising 
the Cys-rich (C) and DSBH (D) regions; see Fig. 1B).  HEK293 cells were transiently 
transfected with vectors in which expression of wild-type or mutant TET1 proteins was 
coupled to expression of human CD25, from an internal ribosome entry site (IRES).  
Control cells (mock) were transiently transfected with a corresponding empty vector that 
drove expression of CD25 alone.  Forty-eight hours after transfection, CD25-expressing 
cells were purified using magnetic beads, and genomic DNA was isolated and digested 
with MspI.  MspI cleaves DNA at the recognition site C^CGG regardless of whether or not 
the second C is methylated, producing cleavage products whose 5’ ends derive from the 
dinucleotide CpG and contain either C or 5mC.  The 5’ phosphates were removed by 
treatment with calf intestinal phosphatase (CIP) and the fragments were end-labeled with 
T4 PNK and [γ-
32P] ATP, yielding a population of molecules labeled predominantly on C 
from the dinucleotide CG (the low-level labeling of other nucleotides reflects DNA 
shearing or contaminating endonucleolytic activity).  The samples were digested with 
snake venom phosphodiesterase and DNase I to generate 5’ dNMP’s, which were 
separated by thin-layer chromatography (TLC) on cellulose plates with unlabeled 
5’dNMP’s included as size standards.  The amount of radioactivity deriving from dCMP 
and 5-methyl-dCMP (5m-dCMP) was then measured by autoradiography and 
phosphorimager scanning.  This method provides a quantitative estimate of the ratio of 
5mC to C at all MspI recognition sites in genomic DNA (Fig. 3A). 
MspI-digested DNA from cells transfected with the control vector yielded predominantly 
dCMP and 5m-dCMP as expected (Fig. 3B, lane 1), whereas DNA from cells expressing 
wild-type TET1-FL or TET1-CD yielded an additional unidentified labelled species (Rf 
~0.29) migrating more slowly than dCMP (Fig. 3B, lanes 2 and 4; for solvent composition   9 
see Methods).  This new species was not detected in MspI-digested DNA from cells 
transfected with mutant versions of TET1 (Fig. 3B, lanes 3 and 5).  The appearance of the 
unidentified species was associated with a concomitant decrease in the abundance of 5m-
dCMP (Fig. 3B, lanes 2 and 4; quantified in Fig. 3C), suggesting that the unidentified 
species might be derived through modification of 5m-dCMP.  TET1-CD-overexpressing 
cells had higher levels of the altered species in their genomic DNA than cells expressing 
TET1-FL (Fig. 3B, lanes 2 and 4); this is likely explained by the higher expression levels of 
the smaller TET1-CD protein relative to the full-length protein (data not shown).  Notably, 
the unidentified species was not detected when DNA from cells expressing wild-type 
TET1 proteins was digested with HpaII, the methylation-sensitive isoschizomer of MspI 
(Fig. 3D).  Since HpaII does not cut CCGG sequences if the second C is methylated, this 
result indicates that the unidentified species may be a derivative of 5mC.  Moreover, 
CCGG sites containing the unidentified species are not cleaved by HpaII. 
To confirm that the unidentified species was not an artifact of MspI digestion, we analyzed 
genomic levels of 5mC using Taq
αI, a methylation-insensitive enzyme that cuts at T^CGA, 
and therefore, like MspI, produces DNA fragments whose 5’ ends contain C or 5mC from 
the dinucleotide CpG.  Again, the unidentified species was observed by TLC in Taq
αI-
digested DNA from cells expressing wildtype, but not mutant, TET1-CD (Fig. 3E), and the 
appearance of this species was associated with a corresponding decrease in abundance 
of 5m-dCMP (Fig. 3F).  In all experiments, expression of wild-type TET1-CD correlated 
with a small but significant increase in the abundance of dCMP (Fig. 3C, F).  Together 
these results demonstrate that expression of wild-type TET1 in HEK293 cells correlates 
with a decrease in the abundance of 5mC as assayed by immunocytochemistry and TLC, 
and with the concomitant appearance of a new nucleotide species as shown in a 
quantitative assay involving restriction enzyme digestion and TLC.  
 
Cells overexpressing TET1 contain increased levels of hmC in their genome 
Because many members of the 2OG and Fe(II)-dependent oxygenase superfamily are 
hydroxylases, we hypothesized that the unidentified species observed in TET1-expressing 
cells was hmC, and that TET1 hydroxylates the 5-methyl moiety of 5mC, converting it to 
hmC.  These hypotheses are consistent with the slower migration of the unidentified 
species on cellulose TLC plates relative to 5m-dCMP and dCMP (Figs. 3B, E).  Since 
hmC and its glucosylated derivatives are known to replace cytosine in the genome of T-  10 
even phages (34) we used hm-dCMP from unglucosylated T4 phage DNA as an authentic 
source of hm-dCMP.  Unglucosylated T4 phage (T4*) DNA was produced by growing T4 
phage in E.coli ER1656, a strain deficient in the glucose donor molecule, UDP-glucose.  
Genomic DNA from T4* phage was digested with Taq
αI, end-labeled, hydrolyzed and 
resolved using TLC.  These experiments confirmed that the novel nucleotide generated in 
cells expressing TET1-CD migrated in a TLC assay similarly to authentic hm-dCMP from 
unglucosylated T4 DNA (Fig. 4A).   
We used a mass spectrometry-based approach to identify the novel nucleotide.  Genomic 
DNA was prepared from unsorted HEK293 cells (Fig. 4A) overexpressing wildtype or 
mutant TET1-CD and digested to 5’ dNMPs.  Following semi-preparative-scale TLC, the 
unknown species migrating with an Rf value of ~0.29 was extracted from the TLC plates 
with water and the extracts were analyzed by high-resolution mass spectrometry (MS).  
Although several species showed a ~2-fold difference in their abundance in DNA from 
cells expressing wild-type compared to mutant TET1-CD, most likely because of variation 
in the amount of resin excised from the respective TLC plates, a singly-charged species 
with an observed m/z of 336.0582, consistent with a molecular formula of C10H15NO8P
-, 
was the only species exhibiting a large (~19-fold) difference in abundance between the 
wild-type and mutant samples (Fig. 4B).  To establish the identity of this compound, we 
performed a series of MS-MS fragmentation experiments at various collision energies (15, 
25, 35 and 50V) in both positive and negative ion modes (Fig. 4C, Suppl. Fig. S3 and data 
not shown).  The observed fragmentation pattern of the 336.0582 Da ion (Fig. 4C, bottom 
panel) was consistent with that of hm-dCMP, and was virtually identical to that of authentic 
hm-dCMP isolated from T4 phage and subjected to MS-MS fragmentation in parallel (Fig. 
4C, top panel).  Taken together with the TLC data, these results identify the new 
nucleotide species present in the TLC assay of DNA from TET1 expressing cells as hmC, 
implying that in cells expressing wild-type but not mutant TET1, a significant proportion of 
5mC is oxidized to hmC.   
 
TET1 hydroxylates 5mC in vitro 
To determine if TET1 was directly responsible for hmC production in transfected cells, we 
expressed Flag-HA-tagged wildtype and mutant TET1-CD in Sf9 insect cells, and purified 
the recombinant protein to near homogeneity (Suppl. Fig. S4A).  The ability of the purified 
proteins to catalyze 5mC to hmC conversion was tested by incubating them with double-  11 
stranded DNA oligonucleotides containing a fully methylated Taq
αI recognition site.  
Conversion of 5mC to hmC was monitored by TLC (Fig. 5A).  Wild-type TET1-CD, but not 
the H1671Y, D1673A mutant, catalyzed robust conversion of 5mC to hmC (Fig 5A, 
compare lanes 2 and 6).  We confirmed that TET1 uses Fe(II) and 2OG as cofactors by 
independently omitting each factor from the enzymatic reactions.  TET1 displayed an 
absolute requirement for both cofactors (Fig 5A, compare lane 2 with lanes 3 and 5).  
Although some 2OG- and Fe(II)-dependent oxygenases show enhanced activity in the 
presence of ascorbate (35), we saw no decrease in TET1-CD enzymatic activity in the 
absence of ascorbate. This is likely due to the fact that DTT, which was included in the 
reaction buffer to counteract the strong tendency of TET1-CD to oxidize (Suppl. Fig S4A-
C), is able to play a similar role to ascorbate in reducing inactive Fe(III)
 to Fe(II) thereby 
protecting the enzyme from oxidative inactivation (Fig. 5A, compare lanes 2 and 4) (36, 
37).  The results are quantified in Fig. 5B.  
We used high-resolution mass spectrometry to demonstrate, as before, that a singly-
charged species at m/z of 336.0582 was the only species at Rf ~0.29 that differed 
significantly (35-fold) in abundance when comparing substrates incubated with wild-type 
and mutant proteins (Fig. 5C).  MS-MS experiments at various collision energies showed, 
as before, that the fragmentation pattern of the species produced by recombinant TET1-
CD was identical to that of authentic hm-dCMP derived from unglucosylated T4 phage 
(Fig. 5D and data not shown).  Under the conditions of our assay, recombinant TET1-CD 
hydroxylated 5mC not only in fully-methylated, but also in hemi-methylated oligonucleotide 
substrates (Fig. 5E).   
Since TET1 was identified as a homolog of the putative thymine hydroxylases JBP1 and 
JBP2, we tested the ability of TET1-CD to hydroxylate thymine in vitro.  Recombinant 
TET1-CD was incubated with double-stranded DNA oligonucleotides containing a SalI 
recognition site (G^TCGAC).  Conversion of thymine to hmU was either very inefficient or 
did not occur (Suppl. Fig. S5), showing specificity of TET1 for 5mC and not for thymine.   
Together these data demonstrate that TET1 is a member of the 2OG and Fe(II)-
dependent oxygenase superfamily with the ability to oxidize 5mC to hmC in double-
stranded DNA.   
   12 
hmC is present in ES cell DNA and its abundance decreases upon differentiation or 
TET1 depletion  
We next asked whether hmC was a normal constituent of mammalian DNA.  Using the 
TLC assay, we compared hmC levels in the sequence CCGG (i.e. in MspI cleavage sites) 
in previously-activated human T cells, mouse dendritic cells, and ES cells. We observed a 
clear spot corresponding to labelled hmC only in ES cells (Fig. 6A), suggesting an 
association of hmC with the pluripotent rather than the differentiated state.  Quantification 
of multiple experiments indicates that hmC and 5mC constitute ~4% and 55-60% 
respectively of all cytosine species in MspI cleavage sites (CCGG) in ES cells (Fig. 6A).   
To examine this relation further, we asked whether TET1 and hmC levels were altered 
when ES cells were differentiated by removal of the cytokine LIF from culture media. 
TET1 mRNA levels declined by 80% in response to LIF withdrawal for 5 days, compared 
to the levels observed in undifferentiated ES cells (Fig. 6B).  In parallel, hmC levels 
diminished from 4.4 to 2.6% of total C species (a decline of ~40% from control levels) 
(Fig. 6C).  The discrepancy (~80% decline of TET1 mRNA levels compared to ~40% 
decline of hmC levels) might be due to the compensatory activity of other TET-family 
proteins.  
Similarly, RNAi-mediated depletion of endogenous TET1 with two different siRNAs 
resulted in an 83-85% decrease in TET1 mRNA levels and a corresponding ~38% 
decrease in hmC levels (Fig. 6D, E).  Again, the discrepancy is likely due to the presence 
of TET2 and TET3, which are both expressed in ES cells.  These data strongly support 
the hypothesis that TET1, and potentially other TET family members, are responsible for 
hmC generation in ES cells under physiological conditions.  
 
 
Discussion 
We have identified TET1, a member of the TET/JBP family of enzymes, as a 2OG and 
Fe(II)-dependent enzyme capable of oxidizing 5mC to hmC both in cells and in vitro.  
Members of the TET subfamily (TET1, TET2 and TET3) are conserved in jawed 
vertebrates and are broadly expressed in many cell types (30).  All three paralogs are 
likely to possess catalytic activity, as the residues predicted to be necessary for activity 
are fully conserved.     13 
hmC is a normal constituent of mammalian DNA, at least in certain cell types.  Of the 
limited number of cell types that we analyzed, only ES cells possessed readily detectable 
levels of hmC in MspI cleavage sites (CCGG).  In contrast, hmC was almost undetectable 
in HEK293 cells and two differentiated primary cell types, dendritic cells and previously-
activated T cells.  Consistent with our finding that overexpressed and recombinant TET1 
catalyzed the conversion of 5mC to hmC in HEK293 cells and in vitro respectively, RNAi-
mediated depletion of TET1 in ES cells led to a perceptible loss of hmC.   
Notably, ES cells induced to differentiate in response to LIF withdrawal showed parallel 
decreases in TET1 mRNA expression and hmC levels in genomic DNA, suggesting a 
possible relation between hmC and the pluripotent state of ES cells.  To explore this 
hypothesis in more detail, it will be useful to ask whether hmC and TET proteins localize 
to specific regions of ES cell DNA – for instance, to genes that are involved in maintaining 
pluripotency or that are poised to be expressed upon differentiation.  hmC may not be 
confined to CpGs: nearest-neighbour analyses have shown that whereas somatic tissues 
have negligible non-CpG methylation, 15-20% of total 5mC in ES cells is present in CpT, 
CpA and (to a minor extent) CpC sequences (38). 
What are the biological functions and fate of hmC?  Figure 7 summarizes some 
speculations.  An attractive hypothesis is that hmC (which is a stable base in the genome 
of T-even phages (34) influences chromatin structure and local transcriptional activity by 
recruiting proteins that selectively bind to hmC (Fig. 7B). Conversely, the hmC 
modification might exclude methyl-CpG-binding proteins (MBPs) that normally recognize 
5mC, thus displacing chromatin-modifying complexes that are recruited by MBPs (7, 8).  
In support of this latter scenario, it has already been demonstrated that the methyl-binding 
protein MeCP2 does not recognize hmC (39). 
The stability of hmC contrasts with the well-documented instability of N-linked 
hydroxymethyl adducts generated by the DNA repair enzymes AlkB and the JmjC domain-
containing histone demethylases, which are also members of the 2OG and Fe(II)-
dependent oxygenase superfamily.  These nitrogen-linked adducts spontaneously 
resolve, yielding the unmethylated amino group and formaldehyde (36); in contrast, 
oxidation of carbon-linked methyl groups by JBP1/2 and thymine hydroxylase does not 
result in removal of the methyl adduct via oxidation (22, 25, 40).  This difference, which is 
due to the fact that carbon is a much poorer leaving group than nitrogen, explains our 
ability to detect hmC in genomic DNA.  Nevertheless, hmC has been shown to convert to   14 
cytosine through loss of formaldehyde in photo-oxidation experiments (41) and at high pH 
(42, 43), leaving open the possibility that hmC could convert to cytosine under certain 
conditions in cells (Fig. 7A). 
Another possibility is that hmC is an intermediate in a pathway of passive (replication-
dependent) DNA demethylation (Fig. 7A, B).  The presence of hmC on one strand of the 
dinucleotide CpG has been shown to prevent DNMT1 from methylating its target C in the 
opposite strand (44).  Thus the small but reproducible increase in the relative abundance 
of unmethylated cytosine at C^CGG and T^CGA sites, observed within two days of 
expressing TET1-CD in HEK293 cells (Fig. 3C, F), is consistent with a model in which 
demethylation of 5mC proceeds via hmC.  Even a minor reduction in the fidelity of 
maintenance methylation would be expected to result in an exponential decrease in CpG 
methylation over the course of many cell cycles.  It will be of interest to test if the SAD 
(SRA) domain protein UHRF1, the DNMT1 partner protein that is responsible for its high 
selectivity for hemimethylated CpGs (45), is also less capable of recognizing hemi-
modified hmCpG. 
Alternatively, the presence of hmC might be sensed by specific DNA repair mechanisms 
that replace hmC with C, thus leading to “active” demethylation of DNA (Fig. 7).  In fact, 
bovine thymus extracts have been reported to contain a glycosylase activity specific for 
hmC (46), but this activity has not been further characterized.  Moreover, several DNA 
glycosylases, including TDG and MBD4, have been implicated in DNA demethylation, 
although none of them has shown a convincing activity on 5mC using in vitro enzymatic 
assays (47-50).  Finally, cytosine deamination has also been implicated in demethylation 
of DNA (49-51) .  In this context, it is conceivable that deamination of hmC, which would 
result in its conversion to hmU, might be involved in the conversion of hmC into a 
substrate for repair enzymes.  In support of this hypothesis, high levels of HmU:G 
glycosylase activity have been reported in fibroblast extracts (52). With the description of 
this new derivative of 5mC, it will be important to reexamine the specificity of known DNA 
glycosylases and deaminases for DNA containing hmC and its potential derivatives. 
Why has hmC been overlooked as a normal constituent of mammalian DNA?  With the 
exception of two papers that reported high levels of hmC in genomic DNA isolated using 
unconventional but not standard methods (53), most previous studies describe hmC as a 
rare base that is a probable oxidation product of 5mC (44, 54).  One reason that hmC may 
have been missed is that it might be present at detectable levels only in specific cell types   15 
(ES cells and not differentiated cells).  Another factor may be the relatively low abundance 
of hmC.  In ES cells, hmC is ~4% of all cytosine species in CpG dinucleotides located in 
MspI cleavage sites (CCGG) (Fig. 6C, E).  CpG is ~0.8% of all dinucleotides in the mouse 
genome (55), thus hmC constitutes ~0.032% of all bases or ~1 in every 3000 nucleotides.  
For comparison, 5mC is 55-60% of all cytosines in CpG dinucleotides in MspI cleavage 
sites (Fig. 6A), about 14-fold higher than hmC.  A more trivial explanation is that some 
TLC running buffers do not resolve hmC from C (53).  We were fortunate that our 
experimental design led us to focus on areas of the genome containing CpG dinucleotides 
(and hence enriched for 5mC), and that our TLC running conditions could distinguish 
hmC. 
A full appreciation of the biological significance of hmC will depend heavily on the 
development of tools that allow hmC, 5mC and C to be distinguished unequivocally.  We 
show here that two of the three most commonly used techniques do not meet this 
criterion.  A widely-used mouse monoclonal antibody to 5mC apparently does not 
recognize hmC by immunocytochemistry (Fig. 2A), thus it will be important to reevaluate 
previous reports of DNA demethylation based solely on the use of this antibody.  Similarly, 
the methylation-sensitive restriction enzyme, HpaII, fails to cut hmC (Fig. 3D) as 
previously reported (56), raising the possibility that in some instances hmC-modified DNA 
was incorrectly judged to be methylated.  Another methylation-sensitive restriction 
enzyme, McrBC, is already known to cleave 5mC- and hmC-containing DNA equivalently 
(57), and therefore also does not allow these two nucleotides to be distinguished.  It is yet 
to be determined how bisulfite modification analysis interprets the presence of hmC in 
DNA.  Treatment of DNA with sodium bisulfite promotes the spontaneous deamination of 
cytosine to uracil, while leaving 5mC unaffected; amplification of the sequence of interest 
followed by sequencing allows the precise methylation patterns at a given sequence to be 
determined (58).  It is known that bisulfite reacts rapidly with hmC at the C5 to form a 
stable cytosine 5-methylenesulfonate adduct, which is not readily deaminated (59).  This 
substituted species, which is expected to form base pairs similar to those formed by 
cytosine, could be read by polymerases as C during the amplification steps, resulting in 
the sequence being interpreted as containing 5mC.  Alternatively, polymerases may not 
copy cytosine 5-methylenesulfonate efficiently, in which case the DNA containing this 
adduct would not be amplified effectively and the sequence containing the original hmC 
modification would be underrepresented in the amplified DNA.   16 
Notably, disruptions of the TET1 and TET2 genetic loci have been reported in association 
with hematologic malignancies.  A fusion of TET1 with the histone methyltransferase, 
MLL, has been identified in at least two cases of acute myeloid leukemia (AML) 
associated with t(10;11)(q22;q23) translocation (30, 60).  Homozygous null mutations and 
chromosomal deletions involving the TET2 locus have been found in AML and 
myeloproliferative disorders, suggesting a tumor suppressor function for TET2 (61, 62).  It 
will be interesting to test the involvement of TET proteins and hmC in oncogenic 
transformation and malignant progression. 
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Figure Legends  
Figure 1.  Multiple sequence alignment of the TET/JBP family and representative 
2OG-Fe(II) dependent dioxygenase domains. (A) The cysteine-rich region (C) and the 
core catalytic domain (D) are aligned separately.  The family is unified by the presence of 
a distinctive proline which might result in a kink in the N-terminal conserved helix, and a 
conserved aromatic residue (typically F) in the strand following the first conserved helix.  
This aromatic residue is part of an sx2a signature that is boxed in the alignment (where s 
is small, a is an aromatic residue, and x is any amino acid). The alignment also contains 
the structurally characterized representatives of the dioxygenase superfamily, the 
Chlamydomonas prolyl hydroxylase (P4H) and the E. coli AlkB along with their PDB 
codes.  The proteins are labeled by their gene name and species, separated by 
underscores.  The 95% consensus was calculated from a larger alignment of the TET/JBP 
proteins.  The consensus for the TET-specific C-terminal strands was calculated 
separately from a larger alignment specifically of the metazoan TET homologs.  (B) A 
schematic diagram of the predicted domain architecture of TET1 which includes the 
CXXC-type zinc-binding domain (CXXC, amino acids (aa) 584-624); the cysteine-rich 
region (Cys-rich, aa1418-1610); and the double stranded beta helix domain predicted to 
have 2OG-Fe(II) oxygenase activity (DSBH (D), aa 1611-2074).  The positions of three 
bipartite nuclear localization sequences (NLS) are shown.   
 
Figure 2.  Expression of TET1 in HEK293 cells results in decreased 5mC staining 
intensity. (A) Immunocytochemistry of HEK293 cells transiently transfected for two days 
with empty vector (mock) or plasmids expressing wild-type or mutant HA-TET1 and co-
stained with antibodies specific for the HA epitope (green) or 5mC (red).  Nuclei were 
counterstained with DAPI (blue).  Selected HA-expressing cells are circled for convenient 
comparison.  Cells expressing wild-type TET1 (green) show decreased 5mC staining, 
whereas cells expressing mutant TET1 do not show an overall decrease.  Scale bars, 10 
mm. (B) Quantification of staining intensities using the CellProfiler™ image analysis 
program.  Staining intensities of HA (green) and 5mC (red) were measured in individual 
nuclei (defined by DAPI staining) of all cells in a given field using low magnification 
images (20x).  Data from transfected cell populations (600-1200 cells, pooled from 3   21 
microscope fields) are presented as dot plots (red), superimposed on the corresponding 
dot plots from mock-transfected cells (blue), with each dot representing each individual 
cell.  The same set of mock-transfected cells is shown in the two panels.  The plots show 
data from one experiment, representative of 3-4 independent experiments. (C) The 
population average of 5mC staining intensities of HA-expressing cells (arbitrarily defined 
by HA pixel intensities above the highest intensity observed in mock-transfection) in each 
group of transfected cells are compared with that of mock-transfected cells (set as 1) in 
each experiment. Values are background-subtracted before normalization and are mean ± 
SEM from 3-4 experiments; statistical comparisons are based on ANOVA and 
Bonferroni's post-hoc test.  
 
Figure 3.  The genomic DNA of TET1-expressing HEK293 cells contains a modified 
nucleotide within the dinucleotide CG.  (A) Schematic diagram describing the 
experimental design.  (B-F) Genomic DNA was purified from transfected HEK293 cells 
overexpressing TET1 and cleaved with (B, C) MspI, (D) HpaII or (E, F) Taq
αI, and the 
end-labeled fragments were digested to 5’ dNMPs and resolved by TLC.  Cells expressing 
wild-type but not mutant versions of TET1-FL and TET1-CD show altered relative 
abundance of unmethylated and methylated cytosine, as well as a modified nucleotide 
indicated by ?.  (E, F) The intensities of the spots corresponding to dCMP, 5m-dCMP and 
the unidentified nucleotide (?, subsequently identified as hm-dCMP) from (B) and (E) 
were quantified from three independent transfections and the average amounts are shown 
expressed as a fraction of all cytosine-derived nucleotides.  Error bars represent the s.d. 
of triplicates.  (C) Neither 5m-dCMP nor the modified nucleotide are observed when the 
DNA is digested with HpaII.  The data shown are representative of at least three 
experiments. 
 
Figure 4.  The modified nucleotide is identified as 5-hydroxymethylcytosine.  (A) 
DNA from T4 phage grown in GalU-deficient E.coli ER1656 (T4*), and genomic DNA from 
unsorted populations of HEK293 cells expressing wild-type or mutant TET1-CD, were 
digested with Taq
αI.  In the case of T4* DNA, this results in the production of fragments 
with hmC at the 5’ end.  The end-labeled fragments were hydrolyzed and the resulting 
dNMP’s were separated by TLC.  The modified nucleotide produced in TET1-CD-  22 
expressing HEK293 cells migrates with an Rf of ~0.29 in isobutyric acid:water:ammonia 
(66:20:1), similarly to authentic hmC isolated from T4* phage.  (B) Comparison of LC/ESI-
MS ions present at an Rf of 0.29 in samples derived from genomic DNA of HEK293 cells 
expressing wild-type (wt) or mutant (mut) TET1-CD.  A species with an observed m/z = 
336.06 was significantly more abundant (18.5-fold) in the wildtype sample compared with 
the mutant sample.  (C) Mass spectrometry fragmentation (MS/MS) analysis of authentic 
hm-dCMP (top), and the m/z = 336.06 species isolated from HEK293 cells expressing 
TET1-CD (bottom).  MS/MS analysis was performed in negative ion mode with a collision 
energy of 15 V.  Expected m/z values are shown in red; observed m/z values are shown in 
black (anticipated mass accuracy is within 0.002 Da).  The fragmentation patterns are 
identical, identifying the unknown nucleotide as hm-dCMP.   
 
Figure 5.  Recombinant Flag-HA-TET1-CD purified from Sf9 cells converts 5mC to 
hmC in methylated DNA oligonucleotides in vitro.  (A) 2 µg of double-stranded DNA 
oligonucleotides containing a fully-methylated Taq
αI site  were incubated with 3 µg of 
purified Flag-HA-TET1-CD or mutant Flag-HA-TET1-CD in a buffer containing 1 mM 2OG, 
2 mM ascorbic acid, 75 µM Fe(II) for 3 hours at 37 C (1:10 enzyme to substrate ratio).  
Recovered oligonucleotides were digested with Taq
αI, end-labeled, hydrolyzed to dNMP’s 
and resolved using TLC.  The faint dCMP spot in each lane is derived from end-labelling 
of the C at the 5’ end of each strand of the oligonucleotide substrate. (T4 PNK is not able 
to phophorylate blunt ends as efficiently as the 5’ overhangs generated by restriction 
enzyme cleavage.)  (B) The intensity of dNMP’s was quantified using PhosphorImager 
and the extent of conversion of 5mC to hmC is shown as the ratio (hmC/(hmC+ 5mC)).  
Error bars represent the standard deviation of triplicates.  (C) Comparison of species 
within the TLC spot (Rf = 0.29) of products resulting from synthetic fully-methylated 
double-stranded oligonucleotides incubated with wild-type (wt) or mutant (mut) Flag-HA-
TET1-CD.  (D) Mass spectrometry fragmentation analysis (MS/MS) of authentic hm-dCMP 
isolated from mutant T4 phage (top) and the unidentified nucleotide derived from synthetic 
fully-methylated double-stranded oligonucleotides incubated with wild-type Flag-HA-TET1-
CD (bottom).  MS/MS analysis was performed in negative ion mode with a collision energy 
of 15 V.  Observed masses are shown in black (mass accuracy was within 0.002 Da). The 
fragmentation patterns are identical, identifying the unknown nucleotide as hm-dCMP.  (E) 
Recombinant Flag-HA-TET1-CD is able to hydroxylate 5mC in fully-methylated (full, lanes   23 
5, 6) and hemi-methylated (hemi, lanes 3, 4) DNA oligonucleotide substrates.  Unme, 
unmethylated DNA oligonucleotide (lanes 1, 2). 
 
Figure 6.  hmC is present in ES cell DNA and its abundance decreases upon 
differentiation or TET1 depletion 
(A) Left, TLC showing that hmC is detected in the genome of ES cells, but not dendritic 
cells or T cells.  Right, graph quantifying the relative abundance of 5mC, C and hmC in 
the genomic DNA of ES cells cultured under standard conditions in media containing the 
cytokine LIF.  (B) TET1 mRNA levels decline by ~80% in ES cells induced to differentiate 
by withdrawal of LIF.  (C) The same differentiated ES cells show a corresponding ~40% 
decrease in hmC levels.  (D) Transfection of ES cells using two different RNAi duplexes 
directed against TET1 decreases TET1 mRNA levels by ~75%.  (E) The same TET1-
depleted ES cells show a corresponding ~40% decline in hmC levels. 
 
Figure 7.  Model speculating on the biological role of hmC and its potential as an 
intermediate in DNA demethylation.  (A) Integration of hmC into the known pathways of 
DNA methylation and passive replication-dependent demethylation. Known pathways are 
shown in black and the new findings in this study in red.  Dashed lines and question 
marks are used to indicate pathways that may exist but have not been experimentally 
established.  (B) Potential biological mechanisms involving hmC.  hmC may recruit 
specialized binding proteins; and conversion of 5mC to hmC may displace methyl-binding 
proteins from DNA.  hmC may also be an intermediate that facilitates passive DNA 
demethylation: conversion of 5mC to hmC in hemi-methylated DNA may interfere with 
recognition by DNMT1 and associated SRA-domain proteins.  Finally, hmC may be 
recognised by specialized DNA repair proteins in specific cell types, and so function as an 
intermediate in “active” (repair-mediated) DNA demethylation.    24 
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Tahiliani et al., Figure 768124616     106  GIAGYFDYRGSPV------------ELKSRKTSFTYEHEA--AWPAVFPVVDYVSELYRHVAPERWKAQNDAIPDV--------VRIHGTPFSTLTIN 
68125217     256  GIVGYYDYLTNPT------------QHKCRETEFSRRNWG--LLAQSEPLLKHLDKLYSQLAPMHHHLQRVAIPSQ--------YQLCGTVFSTITVN 
6018045      106  GIAGYFDYRGSPV------------ELKSRKTSFTYEHEA--AWPAVFPVVDYVSEIYRHVAPERWKAQNDAIPDL--------VRIHGTPFSTLTIN 
146078722    106  GIAGYFDYRGSPV------------ELKSRKTSFTYEHEA--AWPAVFPVVDYVSELYRHVAPERWKAQNDAIPDV--------VRIHGTPFSTLTIN 
146081173    256  GIVGYYDYLTNPT------------QHKCRETEYSRRNWG--LLAQSEPLLKHLDKLYSQLAPMHHHLQRVAIPSQ--------YQLCGTVFSTITVN 
134060314    332  GIVGYYDYLTNPT------------QHKCRETEFSRRNWG--LFSQSESLLKHLDKLYSQLAPTHHHLQRVAIPSQ--------YQLCGTVFSTITVN 
134059769    106  GIAGYFDYRGSPV------------ELKSRKTSFTYEHEE--AWSAVFPVVDYVSEIYRHVAPERWKAQNNAIPDL--------VRIHGTPFSTLTIN 
6018041      130  GIAGYFDYRGTPV------------ELKCRKTSFTYEHTK--EWRSVFPMIDYTSAIYKAALPDHWKAQDAAVPDV--------VRIHGSPFSTLTVN 
72391588     307  GILGYYDYLNNPT------------KRKCRMTEFTRRNWGK-IIGPCGELLQLLDQLYKENAPDHYELQRRVIPPE--------YMLFNTVFSTVSVN 
71662347     209  GIVGYYDYLNNPT------------QRKCRETEFTRKNWSS-VVDSCEPFLVALNKLYSECAPTHYKLQRIAIPRH--------YQLFNTVFSTMTVN 
71421637     124  GIAGYFDYRGSPV------------ELKCRKTSFTYENVH--SWPNVFPMIDYVSAIYKAVFPEQWAAQDAAVPDI--------VRIHGSPFSTLTVN 
6018043      106  GIAGYFDYRGSPV------------ELKARKTAFTYEHEK--KWPAVFPLVDYVSEIYKSVMPEHWAAQDSAIPDI--------VRIHGTPFSTLTIN 
135108850      1  ------------------------------VLRATRAQPE--VFAGLSKVGKYLWGVYQNCFPEVAANFQKFVGGIHDD-----WKKTGTPFTTVNVN 
139110457      1  ----------------------------------------------MLMCCLESENLIKKYMPEQYESQKKLIEETTLP-----KYRFGKLFTSSISN 
139186735      1  -------------------------------------------IKAMLMSCLESEKIIKQYMPEQYASQKKLIEETTLP-----EYRFGNLFTSSISN 
140212139      1  ------------------------------------------------------------------------IEETTLP-----KYRFGNLFTSSISN 
143037129    108  GVVGFMDKSAMIR--------------YCRKTAFTKKYFD--NYQEGLPFVKFVDEQYKKLCPEYYNRQKNIAEGTNQN-----YVIPDTSFTTVTVN 
139542046      6  SIFGSLPRIARRN------------DFCRFSAHTKKEIK---NTNIIFSFMNDLINIYKKYLPEQYERDIKVIKESVVEDY---ALNKKSPFLTCNIN 
134535573     10  CIIGSVPRNTRMR------------RMHHNRSSVHRSKAAQTFIKAMVIAGRQSLSVIKELTPELYETHRESVLDRVPE-----QWRFCDLFTSSISN 
135380621    131  GIIGYFDRYDRNQLGNGKTLP----KIPCRTTKFTKEFVE--KWDKCIPFIEEIDKQFSIHIPDRHKVQLERASLTKD------FQIKNTAFSTITIN 
139987906    126  SIIGYADRYPRIP--------------YCRQTAFTEKHFD--MYSQAIPYLQSISKLFEEFLPERWQNQKNEWDKTSED-----FKIHGTVFTTITVN 
136831790    139  NPIGFYESSNNFS------------KLPCRLTHFTRTNFD--KYNYGLPFIQKIDSLFKCLIPDAYKRQLNRANLRDK------FKIPNTSFSTVTIN 
135432669    204  NPIGFYEASKNFC------------HLPCRLTHFTRTNFD--DYNKGLPFIQQIDSLFKKLIPDAYKKQLDRANQKPH------LKIPNTSFSTITIN 
144014002    196  NPIGFYEESKNFC------------HLPCRLTHFTRTNFD--DYNKGLPFIQQIDSLFKKLIPDAHEKQLDRANKKPH------LKIPGTSFSTITIN 
136547457    111  NIMGYFDRWSISLRASFKRAGMKP-PTRCRITSFTSRFPE--KWENVVPLIQDIDAQYKRLVPKAYANQRKAADSVK-------FKIPNTSFSTVTTN 
136439712    113  NIIGYMDTWTIQHKYMFSQVGMKEIKPAVRRSYFTQNNYD--NWTPMKSLVKHIDAQYKKLAPVQYKKQRAKADETY-------FKIKGTAFTTLTTN 
144068378    157  NIIGYFDKRDRNLGAN---------APPCRTTAFTSQQVE--KWNNVVPLIKNIDLQFKRLIPSNHRIQYDRANKTD-------FVINGTAFSTVTIN 
134552279    107  NIFGFFDKWSPKQKATFRKLGKKP-DVDVRECRFNMDEPD--KYKKTLPLIKEIDRLYAKLVPVQYKKQKKKARSTH-------FKIDNTAFTTITTN 
113638        60  AMTNCGHLGWTTHRQG--------------------------YLYSPIDPQ-TNKPWPA--MPQSFHNLCQRAATAAGY-----PDFQPDACLINRYA 
548840       607  DHMKGRLAAFYSRDGQ--------------------------GYSYTGYSH--KSQGWL--EGLDKLIEACGEKPT-----------TYNQCLVQKYE 
4505565      383  SAWLSGY------------------------------------------------------ENPVVSRINMRIQDLTGL-----DVSTAEELQVANYG 
159794881     77  GTWFAKG------------------------------------------------------EDSVISKIEKRVAQVTMI-----PLENHEGLQVLHYH 
5923812      427  HIYWYDGYDGR-------------------------------------------AKDAA--TVRLLISMIDSVIQHFKKRIDH-DIGGRSRAMLAIYP 
10437756      77  QITWIGGNEEG----------------------------------------------CE--AISFLLSLIDRLVLYCGSRLGKYYVKERSKAMVACYP 
5805194      511  LKALKLGQEGK--------------------------------------VPLQSAHMYY--NVTEKVRRVMESYF---------RLDTPLYFSYSHLV 
9229924      230  YLAAKLAEKGK--------------------------------------VPPQTAALYY--KLSEEARLQVKMYF---------KLTQELYFDYTHLV 
9658386       62  KIQWLDLSMGQ-------------------------------------------PVQDY--LERMEQIRCEVNRHFF-------LGLFEYEAHFAKYE 
 
 
68124616     ------------SRFRTASHTDVGDFD------------GGYSCIACLDGH--------FKGLALAFDD---------------FGINVLMQPRDVMIFDSH 
68125217     ------------RNFRTAVHTDRGDFR------------SGLGVLSVINGE--------FEGCHLAIKR---------------LKKAFQLKVGDVLLFDTS 
6018045      ------------SRFRTASHTDVGDFD------------AGYSCIACLDGQ--------FKGLALSFDD---------------FGINVLLQPRDVMIFDSH 
146078722    ------------SRFRTASHTDVGDFD------------GGYSCIACLDGQ--------FKGLALAFDD---------------FGINVLMQPRDVMIFDSH 
146081173    ------------RNFRTAVHTDKGDFR------------SGLGVLSVINGE--------FEGCHLAIKR---------------LKKAFQLKVGDVLLFDTS 
134060314    ------------RNFRTAVHTDKGDFR------------SGLGVLSVINGE--------FEGCHLAIKS---------------LKKAFQLKVGDVLLFDTS 
134059769    ------------SRFRTASHTDVGDFD------------AGYSCIACIDGK--------FKGLALTFDD---------------FRINVLMQPRDVMVFDSH 
6018041      ------------ERFRTASHTDNGDFD------------NGYGVLAVLKGE--------YSGLSLALDD---------------YGVCFNMQPTDVLLFDTH 
72391588     ------------KNFRTAVHRDKGDFR------------GGLTALCVLDGN--------YEGCYLALKS---------------ARKAFCLQVGDVLFFDSS 
71662347     ------------RNFRTAVHTDRGDFR------------SGLAALCVIDGV--------FEGCHLAIKK---------------LGKAFRLETGDVLFFDTS 
71421637     ------------QQFRTASHTDAGDFD------------MGYGLLAVLEGK--------FEGLSLALDD---------------FGVCFRMQPRDILIFNTH 
6018043      ------------SRFRTASHTDAGDFD------------GGYSCIACIDGD--------FKGLALGFDD---------------FHVNVPMQPRDVLVFDSH 
135108850    ------------KNFAIGYHVDAANYG------------GVYSNVLITKKN--------IDGGYFVMPQ---------------FKVALAQSHGALVVVDGV 
139110457    ------------YNIAAPYHQDRGNLK------------NTVNVILTKRKT--------SKGGSLHVPD---------------FGHIFKQSNNSILVYPAW 
139186735    ------------YNIAAPYHQDRGNLK------------NTVNVIITKRNQ--------TKGGALSVPD---------------FGHTFEQANNSILIYPAW 
140212139    ------------FNIAAPFHQDRGNLK------------NTVNVILTKRKD--------ADGGALCVPD---------------FGHTFEQSNNSMLVYPAW 
143037129    ------------KNFRTAVHKDAGDFS------------EGFGNLVVYREGD-------WGGGYFILPE---------------YGVGIDLKNTDILFVDVH 
139542046    ------------VNHAIKYHRDSGNFK------------KNLSNVLILRDG--------IIGGELVFPE---------------YGFALSQEDGYLAIFDGQ 
134535573    ------------ANIAAAVHRDNRNVI------------GALNVIVTRRVN--------ATGGNLYLPE---------------YDVTLPSAHNSLTVYPAW 
135380621    ------------LNYRTALHKDKGDLP------------EGFGNLIVLEGDKCGDEKKPYKGGYTGFPQ---------------YKVAVDVRTGDFLAMDVH 
139987906    ------------KNFRTACHYDAGDLK------------EGFGNLAVLQTGE-------YEGAYTVIPK---------------YGVAVDVRNCDIAFFDVH 
136831790    ------------RNFRTALHRDAGDFK------------GGFGNLTVIERGK-------YHGGYTVFPQ---------------YGIGIDLRNNDFVAMDVH 
135432669    ------------RNFRTALHRDAGDFK------------EGFGNLTVIERGK-------YHGGYTVFPQ---------------FGVAVDVRSGDFLAMDVH 
144014002    ------------RNFRTALHRDAGDFK------------GGFGNLTVIERGK-------YHGGYTVFPQ---------------FGVAVDVRSGDFLAMDVH 
136547457    ------------LNFRTAAHHDSGDWD------------EGFGNLVVIERGSK------YGGAYTGFPQ---------------YGVAVDCRQGDFLAMDVG 
136439712    ------------VNFNTCAHTDSGDDE------------DGLGNLVVLQRGE-------YEGGETCFIQ---------------YGVGVDVRETDFLLMDVH 
144068378    ------------YNWRTALHKDAGDLK------------EGFGNLVVLEEGD-------YEGGCTGFPQ---------------FKVAVDCRHGDFLAMDVH 
134552279    ------------VNFRTTIHTDKGDDE------------EGFGNLVVIEKGD-------YTGGETCFPQ---------------YGIGVNVRKGDMLFMDVH 
113638       ------------PGAKLSLHQDKDE--------------PDLRAPIVSVSLG-------LPAIFQFGGLKRND-----------PLKRLLLEHGDVVVWGGE 
548840       ------------QGSRIGFHSDEQAI-------------YPKGNKILTVNAA-------GSGTFGIKCAKG--------------ETTLNLEDGDYFQMPSG 
4505565      ------------VGGQYEPHFDFARKDEPDAFKEL---GTGNRIATWLFYMSDV-----SAGGATVFPEVG---------------ASVWPKKGTAVFWYNL 
159794881    ------------DGQKYEPHYDYFHDPVNAGPEH-----GGQRVVTMLMYLTTV-----EEGGETVLPNAEQKVTGDGWSECAKRGLAVKPIKGDALMFYSL 
5923812      G-----------NGTRYVKHVDNPVK--------------DGRCITTIYYCNENWDMATDGGTLRLYPETS------------MTPMDIDPR-ADRLVFFWS 
10437756     G-----------NGTGYVRHVDNPNG--------------DGRCITCIYYLNKNWDAKLHGGILRIFPEGK------------SFIADVEPI-FDRLLFFWS 
5805194      CRTAIEESQAERKDSSHPVHVDNCILNAESLVCIKEPPAYTFRDYSAILYLNGDF----DGGNFYFTELDAK-----------TVTAEVQPQ-CGRAVGFSS 
9229924      CRTTVKGKPVKRTDLSHPVHSDNCLLK-ENGSCLKERPAYTWRDYSAILYLNDEF----EGGEFIMTDATAR-----------RVKVQVRPK-CGRLVSFSA 
9658386      ------------AGDFYLKHLDSFRG-------------NENRKLTTVFYLNENWTPA-DGGELKIYDLQD------------NWIETLAPV-AGRLVVFLS  
 
 
68124616     ---------HFHSNTEVELS-----------------------FSGEDWKRLTCVFYYRA   264 
68125217     ---------LEHGNTEVVN-------------------------PEIHWQRTSVVCYLRT   412 
6018045      ---------HFHSNTEVELS-----------------------FSGEDWKRLTCVFYYRA   264 
146078722    ---------HFHSNTEVELS-----------------------FSGEDWKRLTCVFYYRA   264 
146081173    ---------LEHGNTEVVN-------------------------PEIHWQRTSVVCYLRT   412 
134060314    ---------LEHGNTEVVH-------------------------PENHWQRTSIVCYLRT   488 
134059769    ---------HFHSNTEVEVS-----------------------CSEEDWKRLTCVFYYRT   264 
6018041      ---------LFHSNTELEAK-----------------------EANATWNRLSCVFYYRA   288 
72391588     ---------LEHGNTEVHNR-------------------------EGSWRRISIVCYLRC   464 
71662347     ---------LEHGNTEVHNF-------------------------DYCWKRVSVVCYLRN   366 
71421637     ---------FFHSNTEPELNH-----------------------PRDDWSRLTCVCYYRA   282 
6018043      ---------YFHSNSELEISC-----------------------PTEEWRRLTCVFYYRS   264 
135108850    S--------IPHGVTPIIP-------------------------KAKNWERSSVVFYTLS   143 
139110457    Y--------NIHGVTKIVR-------------------------ENEQSYRNSLIFYPLQ   129 
139186735    F--------NIHGVTKIIK-------------------------EHEQGYRNSLIFYPLK   132 
140212139    Y--------NIHGVTKIIK-------------------------HKEEGYRNSLIFYPLS   103 
143037129    ---------KYHCNTGFTNFTD--------------------------------------   253 
139542046    T--------EIHGVMPIYQ-------------------------TKENPYRASIVYYSLE   167 
134535573    R--------NYHGVTPIEP-------------------------THPGGYRNSLIWYALD   172 
135380621    ---------EFHCNTELTG---------------------------DNYSRLSLVSYLRK   303 
139987906    ---------ELHGNTQTISKK--------------------------PYERISIICYYRK   283 
136831790    ---------QWHSNTPIIETDEDKLFNNTLNNDYKDNPNIGTEGIYTKYTRLSFVCYLRE   323 
135432669    ---------QWHSNTDIYETEEDKIYNDTIDYAFNDNPEVGTVGLDKKYTRLTFVCYLRE   388 
144014002    ---------QWHSNTDIYETEEDKIFNNTIDYAFNDNPEVGTVGLDKKYTRLTFVCYLRE   380 
136547457    ---------RLHGNCPMIP-------------------------GDDTSQRISLVCYLRK   281 
136439712    ---------QLHANTKLKL-------------------------IGKDSIRLSIVSYLRT   283 
144068378    ---------EWHCNTKIKP-------------------------ITKDYSRLSLVAYLRE   318 
134552279    ---------QPHGNLEMKK-------------------------KHPDVERLSVVCYLRK   276 
113638       ------SRLFYHGIQPLKAGF----------------------HPLTIDCRYNLTFRQAG   213 
548840       F-----QETHKHNVVA-------------------------------VTPRLSFTFRSTV   743 
4505565      FASGEGDYSTRHAACPVL-----------------------------VGNKWVSNKWLHE   519 
159794881    KPDGSNDPASLHGSCPTLK-----------------------------GDKWSATKWIHV   226 
5923812      D------RRNPHEVMPVF------------------------------RHRFAITIWYMD   566 
10437756     D------RRNPHEVQPSY------------------------------ATRYAMTVWYFD   214 
5805194      G------TENPHGVKAVT-----------------------------RGQRCAIALWFTL   670 
9229924      G------KECLHGVKPVT-----------------------------KGRRCAMALWFTM   388 
9658386      -------ERFPHEVLEAH------------------------------ADRVSIAGWFRT   193 DAPI
HA
CellProfiler™ cell image analysis: Quantification of HA and 5mC signals in individual cells
Tahiliani et al. Suppl. Figure 2 Tahiliani et al. Suppl Figure 3 
A B
m/z
81.0399
124.0508
142.0612
81.0397
124.0533
142.0644 Unidentified 
Nucleotide 
Species 
Authentic 
hm-dCMP
(T4* DNA)
Positive, Ion Mode, 25 V
50 100 150 200 250 300 350
0
20
40
60
80
100
50 100 150 200 250 300 350
0
20
40
60
80
100
m/z
78.9585
96.9690
122.0353
140.0462176.9953
195.0057
78.9583
96.9686
122.0348
140.0451
176.9947
195.0052
Authentic 
hm-dCMP
(T4* DNA)
Unidentified 
Nucleotide 
Species 
Negative Ion Mode, 25 VC
TET1-CD 
TET1-D
TET1-CD 
TET1-D
Laemlli 
SDS sample
Buffer RIPA
250
150
100
75
50
Oxidized 
TET1-CD
TET1-CD
B
TET1-CD 
TET1-CD mut 
250
150
100
75
50
Oxidized 
TET1-CD
TET1-CD
D HA-TET1-D HA-TET1-CD HA-TET1-CD mut
HA
5mC
DAPI
A
2 1 0.5 TET1-CD 
TET1-CD mut
250
150
100
75
50
Expected size for TET1-CD
Oxidized 
TET1-CD
*
*
Degradation products?
BSA (µg)
Tahiliani et al., Suppl. Fig. 4 Tahiliani et al., Suppl. Fig. 5 
5'-TGCTACCTCCTCAACGTCGACCACCGTCTCCTGCA-3'
3'-ACGATGGAGGAGTTGCAGCTGGTGGCAGAGGACGT-5'
SalI
A
5’-CTATACCTCCTCAACTTmCGATCACCGTCTCCGGCG-3’
3’-GATATGGAGGAGTTGAAGmCTAGTGGCAGAGGCCGC-5’
TaqαI
TaqαI SalI
5m-dCMP
dAMP
dCMP
dTMP
dGMP
hm-dCMP
Pi, hm-dUMP
dTMP
TET1-CD - + - + hm-
dUMP
BSupporting online material 
 
 
Supplemental Figure Legends 
Supplemental Figure S1.  Sequences used to generate the position-specific score 
matrix (PSSM). The sequences provided in the alignment represent those used to 
create the position specific score matrix for searches with the PSI-BLAST program.  
Each sequence is identified by the gi number allowing its recovery from the GenBank 
database and the numbers flanking the alignment provide the limits of the aligned region 
in the sequence. The JBP proteins from kinetoplastids are marked in red. This alignment 
was used in the manner described in the article for the sequence search strategy leading 
to the detection of the TET proteins and their homologs. The searches were performed 
using the checkpoint start option –B, with the –h set to 0.01 and –F was set to F and the 
all JBP sequences were cycled through the –i options for individual searches. 
The TET/JBP family is defined by all 2OG-Fe(II) oxygenases that are closer to the 
kinetoplastid JBP proteins and the metazoan than any other family of dioxygenases.  
They are characterized by a synapomorphic extended α-helix just N-terminal to the first 
core strand.  The TET/JBP family can further be divided based on sequence features 
and similarity score based clustering in several distinct subfamilies with highly distinctive 
phyletic patterns.  These include: 1) the TET subfamily found in metazoans; 2) the JBP 
subfamily found in kinetoplastids and uncharacterized marine microbes; 3) the fungal-
algal subfamily found in basidiomycete fungi and chlorophyte algae; 4) gp2 subfamily 
found in actinophages Cooper and Nigel of Mycobacteria and Frankia prophage and 
several uncultured viruses from marine samples.  The fungal-algal subfamily is greatly 
expanded in the basidiomycete fungal genomes and is present in 35-60 paralogous 
versions per genome.  The ParB protein, which is associated with members of the 
bacteriophage gp2 subfamily in conserved operons, belongs to a superfamily of proteins 
implicated in DNA-binding and chromosome segregation, suggesting that gp2 might 
interact with the ParB protein in these functions.  In other phages the ParB protein 
shows fusions with DNA methylases, and these enzymes have been implicated in 
replication or chromosome partitioning in enterobacteriophages such as P1 (1).  This 
suggests that the actinophage gp2 might further modify methylated bases or reverse 
their methylation to regulate these processes in viruses possessing them.  As these viral versions are the smallest members of the TET/JBP family and comprise more or less of 
the minimal 2OG-Fe(II) oxygenases catalytic domain, they could potentially be the 
ancestral versions, which spawned the eukaryotic versions. 
 
Suppl. Fig. S2.  Image analysis using CellProfiler.  Nuclei were outlined based on 
DAPI fluorescence using the IdentifyPrimAutomatic module and denoted as Outlined 
Nuclei.  Objects within a pre-set diameter range of 10-35 pixel units are outlined in green 
and included in analysis.  Objects outside the range (including cell clusters) as well as 
those touching the borders are outlined in red and excluded from analysis.  To account 
for HA staining at nuclear boundaries, an IdentifySecondary module was added to 
expand the nuclear outlines by 2 pixels, denoted as ExpandedNuclei Outlines. The 
MeasureObjectIntensity module was then used to apply the ExpandedNuclei Outlines on 
the corresponding HA image, and the Outlined Nuclei on the corresponding 5mC image 
(not shown), to measure pixel intensities of HA and 5mC staining respectively.  Pixel 
numbers are indicated at the axes of images, which are taken with at a magnification of 
20x. 
 
Supplemental Figure S3.  Mass spectrometry fragmentation analyis (MS/MS) of 
authentic hm-dCMP from T4* phage (top) and the unidentified nucleotide species 
present in genomic DNA from HEK293 cells overexpressing TET1-CD (bottom). (A) 
MS/MS analysis was performed in  negative ion mode with a collision energy of 25 V. 
(B) MS/MS analysis was performed in  positive ion mode with a collision energy of 25 V. 
Observed masses are shown (anticipated mass accuracy was within 0.003 Da).    
 
Supplemental Figure S4.  Purification of recombinant Flag-HA-TET1-CD from Sf9 
cells and characterization of TET1-CD fragment.  (A) Coomassie-stained SDS-PAGE 
gel of wild-type and mutant Flag-HA-TET1-CD purified from Sf9 cells to near 
homogeneity by affinity chromatography with anti-Flag antibody conjugated beads.  
Known amounts of BSA were loaded on the same gel for comparison.  Wild-type and 
mutant TET1-CD (79 KDa, indicated by the arrow) both demonstrate a strong tendency 
to oxidize and form disulfide-linked dimers (158 KDa) and higher-order multimers, which 
are resistant to DTT. Asterisks denote degradation products that are not detected by 
immunoblotting (see (B)), probably due to loss of the N-terminal Flag-HA epitope tag.  (B) The bands of higher apparent molecular weight were identified as TET1 oxidation 
products by immunoblotting with an anti-HA antibody.  (C) Immunoblot with anti-Flag 
antibody showing that the multimeric forms TET1-CD increase with increased 
processing time of lysates and concomitant exposure to oxidizing conditions.  A twenty 
minute lysis in 10 mM DTT-containing RIPA buffer (non-denaturing) results in the 
detectable presence of a TET1-CD dimer.  This dimer is not detected when cell pellets 
from Flag-HA-TET1-CD overexpressing cells are lysed directly in Laemlli SDS sample 
buffer (denaturing).  The tendency of TET1-CD to oxidize appears to be due at least in 
part to disulfide bond formation by the Cys-Rich region (C) that is N-terminal to the 
DSBH (D) region. Removal of the N-terminal Cys-Rich region resulted in expression of a 
protein (Flag-HA-TET1-D) that runs at its expected molecular weight (57.6 KDa), even 
when proteins in the lysates are exposed to oxidizing conditions.  Together the data 
shown in (A-C) suggest that intermolecular disulfide bonds that are formed during 
oxidation, and involve a physiological homodimerization interface that is not accessible 
to reducing agents under native conditions where protein-protein interactions are 
maintained.  (D) Overexpression of Flag-HA-TET1-CD in HEK293 cells, but not Flag-HA-
TET1-D, results in decreased staining by an anti-5mC antibody.  
 
Supplemental Figure S5.  Recombinant Flag-HA-TET1-CD purified from Sf9 cells 
does not convert thymine (another 5-methylpyrimidine) to hmU in vitro.  (A) 2 µg of 
double-stranded DNA oligonucleotides containing a fully-methylated Taq
αI (T^
mCGA) or 
a SalI (G^TCGAC) site were incubated with 3 µg of purified Flag-HA-TET1-CD or mutant 
Flag-HA-TET1-CD in a buffer containing 1 mM 2OG, 2 mM ascorbic acid, 75 µM Fe(II) 
for 5 hours at 37 C (1:10 enzyme to substrate ratio).  Recovered oligonucleotides were 
digested with Taq
αI or SalI, end-labeled, hydrolyzed to dNMP’s and resolved using TLC. 
TET1-CD is able to hydroxylate 5mC, but is not able to act on thymine in the context of a 
SalI site in a double-stranded oligonucleotide substrate in vitro.  A double-stranded DNA 
oligonucleotide terminating in hmU was end-labelled and hydrolyzed to generate a 
standard for hm-dUMP migration (lane 5).  SalI has been demonstrated to cleave 
G(hmU)CGAC equivalently to GTCGAC (2). 
 
 Methods 
Computational and bioinformatic analyses.  The non-redundant (NR) database of 
protein sequences (National Center for Biotechnology Information, NIH, Bethesda) was 
searched using the PSI-BLAST programs (3).  Profile searches using the PSI-BLAST 
program were conducted either with a single sequence or a sequence with a PSSM 
used as the query, with a profile inclusion expectation (E) value threshold of 0.01, and 
were iterated until convergence (3). For all compositionally biased queries the correction 
using composition-based statistics was used in the PSI-BLAST searches (4). Multiple 
alignments were constructed using the Kalign program (5), followed by manual 
correction based on the PSI-BLAST results. The multiple alignment was used to create a 
HMM using the Hmmbuild program of the HMMER package (6). It was then optimized 
with Hmmcaliberate and the resulting profile was used to search a database of 
completely sequenced genomes using the Hmmsearch program of the HMMER package 
(6). Profile-profile searches were performed using the HHpred program (7, 8).  The 
JPRED program (9) and the COILS program were used to predict secondary structure. 
Globular domains were predicted using the SEG program with the following parameters: 
window size 40, trigger complexity=3.4; extension complexity=3.75 (10). 
The Swiss-PDB viewer (11) and Pymol programs were used to carry out manipulations 
of PDB files.  Reconstruction of exon-intron boundaries was done using the NCBI Splign 
program with the tblastn searches against chromosomes as a guide. Gene 
neighborhoods were determined using a custom script that uses completely sequenced 
genomes or whole genome shot gun sequences to derive a table of gene neighbors 
centered on a query gene. Then the BLASTCLUST program is used to cluster the 
products in the neighborhood and establish conserved co-occurring genes. These 
conserved gene neighborhood are then sorted as per a ranking scheme based on 
occurrence in at least one other phylogenetically distinct lineage (“phylum” in NCBI 
Taxonomy database), complete conservation in a particular lineage (“phylum”) and 
physical closeness on the chromosome indicating sharing of regulatory -10 and -35 
elements.  Phylogenetic trees were constructed with the MEGA4 package. 
 
 
TET1 expression plasmids  TET1 ORF was amplified from SY5Y cDNA and the 
human clone and inserted into XhoI and NotI sites of an Flag-HA tagged pOZ-N.  Mutant 
TET1 (H1671D, Y1673A) was generated using the QuikChange Mutagenesis Kit (Stratagene).  The sequences of all clones were confirmed by conventional DNA 
sequencing.  Wild-type and mutant Flag-HA-TET1-CD was amplified and cloned into 
Acc651 and XbaI sites of pEF1 (Invitrogen).  The IRES-CD25 of pOZ-N was amplified 
and cloned into the the Acc65I and BstB1 sites of Flag-HA-TET1-CD-pEF1. Wild-type 
and mutant Flag-HA-TET1-CD was amplified from Flag-HA-TET1-CD-pOZ and inserted 
into SalI and NotI sites of pFastBac (Invitrogen). 
 
Immunocytochemistry  Cells were plated on sterile coverglass in 24-well plates at 1.5 
x 10
5 cells/well and grown overnight before transient transfection with pEF1-TET1 
expression constructs or empty vector (mock) using TransIT™-293 transfection reagent 
(Mirus, Madison, WI) according to manufacturer’s instructions. At 42-44 hr post-
transfection, cells were fixed for 15 min in 4% paraformaldehyde in PBS and 
permeabilized with 0.2% Triton X-100 in PBS for 15 min at room temperature. For 
detection of 5-methylcytosine, cells were treated with 2N HCl at room temperature for 30 
min and subsequently neutralized for 10 min with 100 mM Tris-HCl buffer, pH 8.  After 
extensive washes in PBS, cells were blocked for 1 hour at room temperature in 1%BSA, 
0.05% Tween 20 in PBS. Rabbit anti-HA polyclonal antibody (diluted at 1:400; Santa 
Cruz Biotechnology, Santa Cruz, CA ) and mouse anti-5 methylcytosine clone 162 33 D3 
antibody (diluted at 1:2500-3000; Calbiochem, San Diego, CA) were added in blocking 
buffer for 2-3 hours at room temperature and detected concurrently by secondary 
antibodies coupled with Cy2 or Cy3 respectively. DNA was stained with 250 ng/ml of4’,6-
diamidino-2-phenylindole (DAPI) and mounted in SlowFade® Gold antifade reagent 
(Molecular Probes, Eugene, OR). Images were recorded digitally on a Zeiss Axiovert 
200 inverted microscope equipped with a CCD cameraby using OpenLab imaging 
software (Improvision, Coventry, UK). The quantification of nuclear size was performed 
on high magnification (63x objective) images using Volocity software (Improvision); the 
HA-stained images were used to distinguish between transfected (HA positive) and non-
transfected (HA-negative) cells and nuclear profiles were drawn on the DAPI-stained 
images for nuclear area measurements.  
 
CellProfiler™ cell image analysis.  Three fields, containing 200-400 cells each, were 
imaged from each well of transfected cells using an 20X objective. Greyscale images 
(tiffs) were uploaded on CellProfiler as three individual files for every field captured 
under the three excitation wavelengths respectively for DAPI, GFP (detection of HA) and Cy3 (detection of 5mC). Nuclear outlines were profiled based on the DAPI staining, with 
a secondary module included to expand the nuclear outlines by another 2 pixels 
(denoted as “expanded nuclei”) to account for HA staining at nuclear boundaries. 
Clustered cells and cells at the edge of fields were excluded. Staining intensities of HA 
and 5mC within individual cells profiled were measured as mean pixel intensities of GFP 
and Cy3 signals, respectively, within the “expanded nuclei” and original nuclei profiles, 
respectively. The raw data were exported on Excel spreadsheets and plotted as dot 
plots of 5mC mean pixel intensities against HA mean pixel intensities for each 
transfection sample.  
 
Transfection and Sorting of HEK293T cells expressing hCD25  HEK293T cells were 
transfected with TET1-CD-IRES-CD25-pEF1 vectors using TransIT transfection reagent 
(MIrius).  After 48 hours, 30 x 10
6 cells were stained with anti-hCD25-PE antibody 
(1:200) (Becton Dickinson) in 1X FACS Buffer (1XPBS, 2% FBS, 1 mM EDTA, 0. 1% 
NaAzide) for 30 min at 4 C.  Cells were washed twice with 1X FACS Buffer.  Cells were 
then stained with anti-PE microbeads (Miltenyi) for 25 min, 4 C and then washed two 
times with 1X FACS Buffer and then once with 1X MACS buffer (1X PBS, 0.5% BSA, 
0.09% Na Azide and 2 mM EDTA).  Cells were resuspended in 2 ml of ice-cold 1X 
MACS Buffer and CD25-positive cells were sorted using AutoMACS cells sorter (Possel.  
Input, flow-through and collected samples were analyzed by FACS to confirm 
enrichment for CD25-positive cells in collected sample.   
 
Analysis of 5mC levels using thin-layer chromatography  Nuclei were prepared from 
CD25-positive cells by resuspension in 1 ml NPB (240 mM sucrose, 7.5 mM Tris, pH 
7.5, 3.75 mM MgCl2, 0,75% Triton-X-100, with 100 µg RNAseA/ml (Qiagen)) and placing 
on ice for 20 minutes.  Cells were spun at 1300 g for 15 min, 4 C and then washed once 
in NPB.  Nuclei were lysed in 650 µl of 1X LB ((10 mM Tris, pH 8.0, 300 mM NaAcetate, 
pH 5.2, 0.5% SDS, 5 mM EDTA, 100 µg RNAseA/ml and 300 µg/ml Proteinase K 
(Roche)) and incubated overnight at 55 C.  An extra 300 µg/ml Proteinase K was added 
in the morning and the samples were left at 55 C for 5 hours.  Samples were extracted 
with equal volumes of phenol, phenol: chloroform: isoamyl alcohol (25:24:1) and 
chloroform: isoamyl alcohol (24:1) and then precipitated with 2 volumes of ethanol.  
Genomic DNA was washed twice with 1 ml of 70% EtOH, dried and resuspended in 10 
mM Tris, 0.1 mM EDTA, pH 8.0 and allowed to resuspend overnight at 32 C. 2 µg of genomic DNA was digested with 100 units of MspI, HpaII or Taq
a1 and 100 µg of 
RNaseA (Qiagen) overnight.  An extra 100 units of restriction enzyme was added in the 
morning incubations were continued for 6 hours. 10 units of calf intestinal phosphatase 
(CIP) (NEB) was added and incubated for 1 hour at 37 C. DNA was purified using 
Qiaquick Nucleotide Removal Kit (Qiagen) as per the manufacturer’s instructions.  400 
ng of eluted DNA fragments were end-labeled with T4 Polynucleotide Kinase (T4 PNK) 
(NEB) and 10 µCi of [γ
32-P]-ATP for 1 hour at 37 C.  Labeled fragments were precipitated 
by the addition of 30 µg of linear polyacrylamide, 1/10 volume of 3 M Sodium Acetate, 
pH 5.2 and 2.5 volumes of ethanol at left at -80 C for 1 hour.  Samples were spun at 
14,000 rpm, for 20 minutes at 4 C and washed twice with 70% EtOH at 25 C.  Pellets 
were resuspended in 30 mM Tris, pH 8.9,15 mM MgCl2, 2 mM CaCl, with 10 µg of 
DNaseI (Worthington) and 10 µg SVPD (Worthington) and incubated for 3 hours at 37 C.  
3 µl was spotted on cellulose TLC plates (20 cm x 20 cm, Merck) and developed in 
isobutyric acid: H20: NH3 (66:20:1).  Plates were analyzed by phosphorimager scanning 
using Phosphorimager Storm 860 scanner software. 
 
Preparation of unglucosylated T4 phage DNA for preparation of hm-dCMP 
standard  T4 phage stock was titred by spotting 10 µl of serial 10X dilutions on an LB 
plate on which 100 µl of an overnight culture of E.coli CR63 in 3 ml of T4 top agar was 
poured and allowed to solidify.  The plate was incubated overnight at 37 C. 10 ml of 
E.coli CR63 OD600 of 0.5 was infected with a single plaque of T4 phage and incubated 
with shaking at 37
0C until the culture cleared (about 2.5 hours). The culture was 
incubated on ice for 10 minutes and then lysed was completed by the addition of several 
drops of chloroform and gentle mixing.  The lysate was titred as described above. 
E.coli ER1656 was grown in LB to OD600 of 0.5 and then infected with 0.2 phage per 
bacterium and incubated at 37
0C with shaking until the culture cleared (about 8 hours)..  
The culture was chilled on ice for 10 minutes and then lysis was completed by the 
addition of 1 ml of chloroform. DNase I was added to 1 mg/ml and the culture was 
incubated for 2 hours at 4
0C.  The lysate was centrifuged at 12,000g for 10 min at 4 C to 
pellet debris.  The supernatant was collected and phage were pelleted by centrifugation 
at 23,500g for 1.5 hours at 4 C.  The phage pellet  was left covered in TE overnight to 
resuspend.  Phage DNA was extracted using an equal volume of phenol, phenol: 
chloroform: isoamyl alcohol (25:24:1) and chloroform: isoamyl alcohol (24:1).  The 
extracted phage DNA was dialyzed into TE overnight with 2 changes of buffer.  
Mass spectrometry experiments.  Genomic DNA from HEK293 cells transfected with 
TET1 wild-type or mutant CD or T4 phage grown in E.coli 13656 were hydrolyzed to 
dNMP’s with SVPD and DNaseI and resolved using TLC.  Spots corresponding to 
paricular dNMP’s were scraped, extracted with water, lyophilized, and re-suspended in 
water for liquid chromatography/mass spectrometry (LC/MS) analysis using an Acquity 
UPLC/Q-TOF Premier electrospray LC/ESI-MS system (Waters Corp., Milford, MA).  
Liquid chromatography (LC) was performed with a Waters HSS C18 column (1.0mm i.d. 
x 50mm, 1.8-um particles) using a linear gradient of 0% to 50% methanol in 0.1% 
aqueous ammonium formate, pH 6.0.  The flow rate was 0.05 mL per min and the eluant 
was directly injected into the mass spectrometer.  Mass spectra were recorded in 
continuum mode and converted to centroid mode to generate accurate mass spectra. 
Data was analyzed with Masslynx 4.1 software (Waters).  
 
Recombinant Protein Expression and Purification  Bacmid DNA was generated 
using DH10Bac™ E. coli E.coli (Invitrogen) as directed by the manufacturer.  
Transposition into the correct site was confirmed using PCR.  Baculovirus was amplified 
for three generations using suspension adapted Sf9 cells.  Sf9 cells were then infected 
with baculovirus for 4 days.  The resulting cell pellet was kept on ice for 30 minutes in 40 
mM Tris, pH 7.4, 300 mM NaCl, 0.2% NP40, 0.4% Triton, 5 mM DTT, 1X protease 
inhibitors without EDTA (Roche) and then at 12,000 rpm (SLA-TC600), 30 min, 4 C.  The 
supernantant was then incubated with anti-Flag antibody-conjugated beads (Invitrogen) 
for 5 hours at 4 C.  The beads were washed 4 times in 40 mM Tris, pH 7.4, 300 mM 
NaCl, 0.2% NP40, 8% Glycerol, 1X PI, 5 mM DTT and then eluted in 195 mM Tris, pH 
7.4, 110 mM NaCL, 0.14% NP40, 5.8% Glycerol, 0.37X PI, 3.7mM DTT, 365 µg/ml Flag 
peptide. The homogeneity of the eluted protein was determined using SDS-PAGE 
followed by Coomassie blue staining and immunoblotting using an anti-Flag antibody 
(Sigma). 
 
Preparation of double-stranded oligonucleotide substrates 
Synthetic oligonucleotides were purchased from IDT.  All oligonucleotides were 35 
nucleotides in length with the modifications shown below. 
F:  5’-CTATACCTCCTCAACTTCGATCACCGTCTCCGGCG-3’ F
Me:  5’-CTATACCTCCTCAACTT(mC)GATCACCGTCTCCGGCG-3’  
R:  5’-Biotin-CGCCGGAGACGGTGATCGAAGTTGAGGAGGTATAG-3’ 
R
Me:  5’-Biotin-CGCCGGAGACGGTGAT(mC)GAAGTTGAGGAGGTAT AG-3’ 
Oligonucleotides were annealed to the appropriate complementary oligonucleotide in 
100 mM KAc, 30 mM HEPES, pH 7.5.  The mixture was boiled for 5 minutes then slowly 
cooled to room temperature overnight.  Double-stranded oligonucleotides were purified 
by polyacrylamide gel electrophoresis. 
 
In vitro Enzymatic Assays  7.5 µl of recombinant protein (about 3 µg) was incubated 
with 2 µg of oligonucleotide substrates in 50 mM HEPES, pH 8, 50 mM NaCl, 2 mM 
Ascorbic Acid, 1mM 2OG, 75 µM FAS (Fe
2+), and 1 mM DTT for 3 hours at 37 C.  
Oligonucleotide substrates were purified using Qiaquick Nucleotide Removal Kit 
(Qiagen) and then digested with Taq
a1 overnight, treated with CIP for 1 hour and purified 
once more with Qiaquick Nucleotide Removal Kit (Qiagen).  Purified DNA 
oligonucleotides were end-labeled with T4 Polynucleotide Kinase (NEB) and 10 µCi of 
γ
32P-ATP for 1 hour at 37 C.  Labeled fragments were precipitated by the addition of 30 
µg of linear polyacrylamide, 1/10 volume of 3 M Sodium Acetate, pH 5.2 and 2.5 
volumes of ethanol followed by incubation at -80 C for 1 hour.  Samples were spun at 
14,000 rpm, for 20 minutes at 4 C in a refrigerated microcentrifuge. Unincorporated 
radionucleotide was removed by washing two times with 70% EtOH and spinning at 
room temperature for 10 minutes.  Pellets were resuspended in 10 µl 30 mM Tris, 15 
mM MgCl2, 2 mM CaCl, pH 8.9 with 10 µg of DNaseI (Worthington) and 10 µg SVPD 
(Worthington) and incubated for 3 hours at 37 C.  3 µl was spotted on cellulose TLC 
plates (Merck) and developed in isobutyric acid: water: ammonia (66:20:1).  Plates were 
analyzed by phosphorimager scanning using Phosphorimager Storm 860 scanner 
software. 
 
ES cell culture  V6.5 mouse ES cells were maintained on mitomycin c-inactivated primary 
mouse embryonic fibroblasts in ES medium containing DMEM (Invitrogen, Carlsbad, CA), 
15% ES FBS (Omega Scientific, Tarzana, CA) , 0.1 mM each of nonessential amino acids 
(Invitrogen), 2 mM L-glutamine (Invitrogen), 0.1 mM β-mercaptoethanol (Invitrogen), 50 
units/ml penicillin/streptomycin  (Invitrogen) and 1000 U/ml ESGRO
® (LIF; Chemicon). For all 
experiments described, cells were trypsinized and plated for 30 min on standard tissue culture dishes to remove feeder cells before floating ES cells were collected and re-plated on 
gelatin-coated dishes or wells.  For LIF withdrawal assays, cells were plated at a density of 2-
3 x 10
5 cells per 10-cm dish and LIF was removed the day after (day 0). RNA interference 
(RNAi) experiments were performed as previously described using Dharmacon siGENOME 
siRNA duplexes (Thermo Fisher Scientific Inc, Boulder, CO) against mouse Tet1 (Cat. # D-
062861-01/02). The Dharmacon siGENOME non-targeting siRNA#2 (Cat. # D-001210-02) 
was used as a negative control. Mouse ES cells were seeded in gelatin-coated 12-well at a 
density of 1 x 10
5 cells per well and transfected the day after (day 0) with 50 nM siRNA using 
Lipofectamine RNAiMAX reagent (Invitrogen) according to the manufacturer’s instructions. 
Retransfections were performed on pre-adherant cells at day 2 at a split of 1:4 and finally at 
day 4 at a split of 1:2 in 6-well plates. Cells were harvested at Day 5 for RNA and thin-layer 
chromatography analyses.  
 
RNA Isolation, cDNA synthesis and Quantitative Real-Time PCR  Total RNA was 
isolated with an RNeasy kit (Qiagen, Chatsworth, CA) with on-column DNase treatment. 
cDNA was synthesized with 0.5 mg total RNA using SuperScript III reverse transcriptase 
(Invitrogen). Quantitative PCR was performed using FastStart Universal SYBR Green 
Master mix (Roche, Mannheim, Germany) on a StepOnePlus real-time PCR system 
(Applied Biosystems, Foster City, CA) according to the manufacturer’s instructions. The 
levels of gene expression were normalized to Gapdh.  Primer sequences are:  Tet1 
forward 5’-GAGCCTGTTCCTCGATGTGG-3’, Tet1 reverse 5’-CAAACCCACCTGAGGC 
TGTT-3’; Oct3/4 forward 5’-TCTTTCCACCAGGCCCCCGGCTC-3’, Oct3/4 reverse 5’-
TGCGGGCGGACATGGGGAGATCC-3’, Gapdh forward 5’-GTGTTCCTACCCCCAATG 
TGT-3’, Gapdh reverse 5’-ATTGTCATACCAGGAAATGAGCTT-3’.  
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